Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023

Rhea-AI Summary

Trevi Therapeutics, a clinical-stage biopharmaceutical company, will hold a conference call and webcast on November 9, 2023, at 4:30 p.m. ET to provide a corporate update and review financial results for the third quarter. The call will discuss the development of Haduvio™, an investigational therapy for chronic cough in idiopathic pulmonary fibrosis, refractory chronic cough, and prurigo nodularis. Participants can join the call by phone or access the live webcast on the company's website. A replay of the webcast will be available for 30 days.

Conference call and webcast to be held at 4:30 p.m. EDT

NEW HAVEN, Conn., Nov. 1, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough, and prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, November 9, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2023.

To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 5615817. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough, and prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally as well as peripherally in the lungs and has the potential for a synergistic anti-tussive effect to treat chronic cough.

The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant.

Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on Twitter and LinkedIn.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q3-2023-financial-results-and-provide-a-corporate-update-on-november-9-2023-301974717.html

SOURCE Trevi Therapeutics, Inc.

FAQ

When is Trevi Therapeutics holding a conference call and webcast?

Trevi Therapeutics is holding a conference call and webcast on Thursday, November 9, 2023, at 4:30 p.m. ET.

What is the purpose of the conference call and webcast?

The conference call and webcast will provide a corporate update and review the Company's financial results for the third quarter.

What is Haduvio™?

Haduvio™ is an investigational therapy being developed by Trevi Therapeutics for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis, refractory chronic cough, and prurigo nodularis.

How can I participate in the conference call?

To participate in the live conference call, dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 5615817.

Where can I access the live audio webcast?

The live audio webcast will be accessible from the 'Investors & News' section on Trevi Therapeutics' website at www.TreviTherapeutics.com.

How long will the webcast replay be available?

An archived replay of the webcast will be available for 30 days on Trevi Therapeutics' website following the event.